{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:37:51Z","timestamp":1787686671147,"version":"build-2784847793"},"reference-count":30,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:p>PurposeWhile TP53 mutations are well known to be associated with adverse prognosis in hematological diseases, their functional impact remains incompletely understood. This study examines the spectrum of TP53 mutations across various hematologic malignancies and evaluates their functional impact.Materials and MethodsUsing targeted sequencing panels, we analyzed TP53 mutations in the bone marrow aspiration samples of a retrospective cohort of 856 patients diagnosed with hematologic malignancies. To assess the impact of TP53 mutations, we applied the evolutionary action (EAp53) score and the relative fitness score (RFS), previously proposed functional scoring methods. The effects of variant allele frequency (VAF), disruptive mutations, EAp53 score, and RFS on overall survival (OS) were evaluated.ResultsTP53 mutations were associated with inferior OS compared with wildtype TP53 (median OS 10.0 months versus not estimable; hazard ratio (HR) 4.6; p&lt;0.001). In the acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome subgroups, TP53 mutations had a significant adverse impact on OS. (HRs 3.8, 4.2, 6.0, respectively; p&lt;0.001, p=0.005, p&lt;0.001, respectively). Patients with VAF &gt;50% had significantly poorer OS compared to those with VAF \u226450% (median OS 7.5 months versus 22.8 months; HR 2.2, p=0.016). Moreover, patients in the high-risk RFS group (RFS &gt;0.22) had significantly worse OS compared to those in the low-risk RFS group (RFS \u22640.22) (median OS 5.6 months versus 16.3 months; HR 2.2, p=0.041). However, no significant survival difference was observed between the EAp53 high-risk (&gt;75) and low-risk (\u226475) groups, or between patients with disruptive and non-disruptive mutations. ConclusionOur findings highlight VAF and RFS as valuable tools for stratifying TP53-mutant patients into high-risk and low-risk groups.<\/jats:p>","DOI":"10.4143\/crt.2025.297","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:57:57Z","timestamp":1748307477000},"page":"656-663","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Landscape of TP53 Mutations in Hematologic Malignancies"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9129-3838","authenticated-orcid":true,"given":"Seo Yoon","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joowon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Woo","family":"Seong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-8846","authenticated-orcid":true,"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.247452.114"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2641"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.77.060806.091238"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.205"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.028"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.08.004"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7241"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-763086"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902763533"},{"key":"ref12","first-page":"6357","volume-title":"PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells","author":"Zhou","year":"2003"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa073770"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-2735"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.08.013"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200710415"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030637"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003120"},{"key":"ref19","first-page":"1549","volume-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","author":"Bernard","year":"2020"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014472"},{"key":"ref21","first-page":"1200","volume-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","author":"Arber","year":"2022"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.304"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.129"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7182"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30203"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13475"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153286"},{"key":"ref29","first-page":"11753","volume-title":"A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 \u00d7 CD3 bispecific Dart molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies","author":"Winer","year":"2022"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00674-5"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.297","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:32:20Z","timestamp":1776058340000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.297","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2025-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}